刘宝东, 董宗俊, 支修益, 许庆生. pT3期胸下段食管鳞癌术后选择性动脉化疗对远期生存的影响[J]. 中国肿瘤临床, 2005, 32(3): 148-150.
引用本文: 刘宝东, 董宗俊, 支修益, 许庆生. pT3期胸下段食管鳞癌术后选择性动脉化疗对远期生存的影响[J]. 中国肿瘤临床, 2005, 32(3): 148-150.
Liu Bao-dong, Dong Zong-jun, Zhi Xiu-yi, . Clinical Studies on Postoperative Selective Arterial Infusion Chemotherapy in Patients with Pathologic T3 Lower Segment Esophageal Squamous Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(3): 148-150.
Citation: Liu Bao-dong, Dong Zong-jun, Zhi Xiu-yi, . Clinical Studies on Postoperative Selective Arterial Infusion Chemotherapy in Patients with Pathologic T3 Lower Segment Esophageal Squamous Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(3): 148-150.

pT3期胸下段食管鳞癌术后选择性动脉化疗对远期生存的影响

Clinical Studies on Postoperative Selective Arterial Infusion Chemotherapy in Patients with Pathologic T3 Lower Segment Esophageal Squamous Carcinoma

  • 摘要: 目的:评价pT3期胸下段食管鳞癌根治术后选择性动脉灌注化疗对远期生存的影响。方法:1990年1月至1999年1月间进行根治性手术的pT3期胸下段食管鳞癌患者190例,分成实验组108例(T3N0M056例、T3N1M052例)和对照组82例(T3N0M048例、T3N0M034例),并分三次以下化疗组(56例)和三次以上化疗组(52例)。实验组于术后3~4周腹腔动脉灌注顺铂+5-氟脲嘧啶,每4~6周一次,所有患者全部随访。结果:动脉灌注化疗组与对照组间远期生存无统计学差异,即使是有淋巴结转移组动脉化疗也不延长生存期,但3次以上动脉化疗可以延长生存期。结论:动脉灌注化疗对pT3期胸下段食管鳞癌患者不能延长远期生存率,即使有淋巴结转移也不能延长生存期,但3次以上动脉化疗可以延长生存期。

     

    Abstract: Objective :To evaluate the influence of the longterm survival in pT3 lower segment esophageal squamous carcinoma after radical surgery by selective arterial infusion chemotherapy. Methods : One hundred and eight (T3N0M0 56 and T3N1M0 52) of the 190 patients with pathologic pT3 lower segment esophageal squamous carcinoma, confirmed by consecutive radical surgery from January 1990 to January 1999, were divided into the experimental group (surgery + intra-arterial infusion), and the rest were divided into the control group(surgery alone, T3N0M0 48 and T3N1M0 34). The experimental group was subgrouped into 56 cases(T3N0M0 26 and T3N1M0 30) with less than 3 periods 3 times of therapy, and 52 cases (T3N0M0 30 and T3N1M0 22) with more than 3 times of therapy (including 3 times) . We adopted one to seven courses of selective arterial infusion chemotherapy with cisplatin (80 mg/m2 of body-surface area) and fluorouracil (800 mg/m2) with or without epirubicin 3 or 4 weeks after operation. The interval for each periods was 3 to 4 weeks. All cases were followed-up for more than 5 years. The survival rate was calculated by the method of Kaplan-Meier and the survival difference between the patients with and without selective arterial infusion chemotherapy was compared with log-rank test. Prognostic variables were enterd into a Cox regression model controlling for age, site, lymph node status, and treatment received. Results : The overall suevival rate had no significant difference between the experimental groups and control group in this experimental, but there was a better suevival rate in receiving more than 3 courses of chemotherapy (including 3). Conclusion : Transcatheter arterial infusion chemotherapy is a safe and effective method, postoperative selective arterial infusion chemotherapy can prolong the survival rate in patients with esophageal squamous carcinoma, who have previously underwent the radical surgery. However, further investigation will be needed in future.

     

/

返回文章
返回